sarqa/dkg conference 3-4 october 2002 1 sarqa/dkg conference 3-4 october 2002 annex 13 update an...
TRANSCRIPT
SARQA/DKG Conference 3-4 October 2002
1
SARQA/DKG Conference
3-4 OCTOBER 2002
Annex 13 Update
An Industry Perspective
Michael J Cooke
Director, Global GMP QA
AstraZeneca
SARQA/DKG Conference 3-4 October 2002
2
Annex 13 Update
• Introduction
• Revision to Annex 13
• Issues and Concerns
• Role of the Qualified Person
• Other Challenges for the CT Directive Implementation
SARQA/DKG Conference 3-4 October 2002
3
Annex 13 Update
• Timings
• Draft issued November 2001
• Comments submitted May 2002
• End of Year for Issue ?– As for other guidance documents ?
SARQA/DKG Conference 3-4 October 2002
4
Annex 13 Update
Proposed Changes :
• Some are welcome !• Removal of the 25% rule for dating of
comparator products• Removal of requirement to retain
unused product until after finalisation of the clinical trial
SARQA/DKG Conference 3-4 October 2002
5
Annex 13 Update
(1) Product Specification File (para 11)• Specifications, analytical methods• Manufacturing methods• In process testing and methods• Relevant clinical protocols and
randomisation codes, as appropriate• Stability data and Storage and shipment
conditions
SARQA/DKG Conference 3-4 October 2002
6
Annex 13 Update
(1) Product Specification File (cont)• Relevant Technical agreements with contract
givers • Single File • “Approved” and referenced on the Order
(para 10)• How to ensure its up to date ?• How will the Qualified Person be kept up to
date with PSF ?
SARQA/DKG Conference 3-4 October 2002
7
Annex 13 Update
(2) Labelling Requirements (para 29)
(a) Name, address, telephone number– inflexible supply for multi-national
trials– Suggest name only
(b) As written, implies name/identifier of the product for blinded trials
SARQA/DKG Conference 3-4 October 2002
8
Annex 13 Update
(2) Labelling Requirements (cont)
(d) Trial subject identification number on label
– May be added at time of dispensing to retain flexibility of supply
– Expectation for inspections ?
SARQA/DKG Conference 3-4 October 2002
9
Annex 13 Update
j) “Use by” date
• Product may require re-labelling (36)– Should be at manufacturing site– Alternatively, at investigator’s site by
trial pharmacist or maybe by trial monitor
• Option to allow sponsor to provide this information to investigator
SARQA/DKG Conference 3-4 October 2002
10
Annex 13 Update
(2) Labelling Requirements (cont)
• Small label– Legibility and impact may be affected
• Some information may be added at time of dispensing (subject/investigator identification– Provides flexibility in supply
SARQA/DKG Conference 3-4 October 2002
11
Annex 13 Update
(3) Role of the Qualified Person and Assessment of Batches
• Article 13 of Directive 2001/20/EC requires that the Authorisation holder must have a QP at his disposal
• Allows for “transitional arrangements”– Grandfather clause
SARQA/DKG Conference 3-4 October 2002
12
Annex 13 Update
Transitional Arrangements
• “person engaged in activities as the QP for IMP…shall continue the activities in the Member State concerned” (Article 13.5)
• Acceptable to other Member States ?– Movement of IMPs with EU ?
SARQA/DKG Conference 3-4 October 2002
13
Annex 13 Update
IMP Manufactured within EU
• 91/356/EEC (GMP)
• Product Specification File
• Article 9(2) [Authorisation to conduct the trial]
• Certify in Register
SARQA/DKG Conference 3-4 October 2002
14
Annex 13 Update
IMP Manufactured in a Third Country
• GMP equivalent to 91/356EEC
• Absence of MRA, QP must determine the equivalency
• 42.c i) “normally by participation in audit”
SARQA/DKG Conference 3-4 October 2002
15
Annex 13 Update
Multi national organisations
• Frequent transfers between sites
• Same Corporate standards, possibly same QA and function management
• Audit by QP not necessary ?
• How to justify to inspector ?
SARQA/DKG Conference 3-4 October 2002
16
Annex 13 Update
Comparator Products from Third Country
• Requires, for each production batch, documentation is obtained to show equivalent GMP….
• Otherwise ensure each batch has undergone all relevant tests …..
SARQA/DKG Conference 3-4 October 2002
17
Annex 13 Update
Comparator Products from Third Country
• Difficult to get assurance of GMP compliance ?
• Accept Certificate of Analysis ?
• Testing on import ?
• What would be acceptable in the Application ?
SARQA/DKG Conference 3-4 October 2002
18
Annex 13 Update
Comparator Products from Third Country
• Easiest route to source comparator product from EU with a Marketing Authorisation !
SARQA/DKG Conference 3-4 October 2002
19
Annex 13 Update
Assessment of batches may include : (para 43)
• Currently documents listed include many that will not be referenced routinely ?
• Covered by Reference to the Product Specification File ?
SARQA/DKG Conference 3-4 October 2002
20
Annex 13 Update
Assessment of batches may include : (cont)
• Where relevant, results of tests or analysis after importation ?– Why test at all ?– Commercial product requirements ?
• Audit reports of the manufacturer ?
• Stability reports ?
SARQA/DKG Conference 3-4 October 2002
21
Annex 13 Update
Where does the QPs responsibility end ?
• Expiry date extensions ?
• Re-labelling ?
• Randomisation ?
• Manufacture v Dispensing ?
SARQA/DKG Conference 3-4 October 2002
22
Annex 13 Update
Other comments - Para (6)
• Not clear whether the QP’s responsibility to fulfil “these requirements” relates to all requirements of the annex or just to the training of these.
• Broad knowledge of “clinical trial processes” does not include manufacture of supplies
SARQA/DKG Conference 3-4 October 2002
23
Annex 13 Update
Other comments – Batch release of Products• Table 1
– Confusing, “before “ and “after” clinical trial processing
– (e) implies testing in EU is required for IMPs and comparators from outside of EU
– Contrary to Directive 13.3 (b) and (c ) which requires the QP to confirm testing has been carried out
– No mention of testing in 42c) (i)
SARQA/DKG Conference 3-4 October 2002
24
Annex 13 Update
Other Comments –Para 47
• Requirement for de-coding documents to be accessible before shipped to investigator site –restrictive
• Propose “before dispensed” at …site
SARQA/DKG Conference 3-4 October 2002
25
Annex 13 Update
Other comments – Para 51
• Requirement for Investigator to understand the procedures for retrieving IMPs - not appropriate or necessary
• Propose .. “investigator and monitor need to understand their obligations under the retrieval procedure”
SARQA/DKG Conference 3-4 October 2002
26
Annex 13 Update
Other comments –Para 55
• implies destruction at the manufacturing site…
SARQA/DKG Conference 3-4 October 2002
27
Annex 13 Update
Summary
• Few changes in proposed draft are welcomed but ….
• Further amendments/deletions necessary to simplify, clarify and ensure appropriate level of control
SARQA/DKG Conference 3-4 October 2002
28
Annex 13 and GCP Directive
91/356/EEC current draft revision
• Added “importer” after “manufacturer” without adequate attention to the impact of the meaning
• Further amendments to simplify and clarify
SARQA/DKG Conference 3-4 October 2002
29
Annex 13 and GCP Directive
Requirements for Authorization referred to in Article 13, Directive 2001/20EC
• Information should “high level”, not detailed– Minimise bureaucracy ?
• Should not be more demanding than for commercial products – Proof of legal status ?
SARQA/DKG Conference 3-4 October 2002
30
Annex 13 and GCP Directive
Requirements for Authorization referred to in Article 13, Directive 2001/20EC
• Alternative approach ?
• information complied similar to “Plant Master File” presented to local inspectors
• Mutual recognition of inspections if IMP manufactures